文献速递肝胆胰外科

胰切除后残余胰腺复发胰腺癌的切除治疗具有临床前景:日本肝胆胰外科学会项目研究

Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: Results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.
PubMed 文献 · Surgery · 2018-07-29

该多中心回顾性调查分析了114例初次胰切除后残余胰腺复发胰腺癌患者的临床数据,评估手术指征与预后。多因素分析显示年龄≥65岁、BMI<20、肿瘤≥20mm、距胰断端<10mm及切除残余胰腺癌为显著预后因素。

要点

  • 年龄≥65岁、BMI<20、肿瘤≥20mm、距胰断端<10mm及未切除为不良预后因素。
  • 再次胰腺切除术后Clavien-Dindo III级及以上并发症8.9%,90天死亡率1.1%。

核心结论

  • 切除残余胰腺癌可提供良好结局和治愈机会,尤其年轻健康、肿瘤较小且距胰断端至少10mm的患者是最佳再手术候选。
  • 再次手术的安全性可接受,Clavien-Dindo III级及以上并发症8.9%,90天死亡率1.1%。

研究设计与样本

  • 日本肝胆胰外科学会开展的多中心回顾性调查,收集114例初次胰切除后残余胰腺复发胰腺癌患者的临床数据。
  • 分析临床病理因素和总生存曲线,采用多因素Cox比例风险模型评估。

主要发现

  • 再次胰腺切除后按复发模式分类,无复发组中位生存30.5个月,局部复发组32.0个月,远处转移组23.0个月。
  • 年龄≥65岁、BMI<20 kg/m2、肿瘤大小≥20mm、距胰断端<10mm及切除残余胰腺癌为显著预后因素。

关键数值与推荐

  • 年龄(≥65岁)、体重指数(<20 kg/m2)、肿瘤大小(≥20mm)、距胰断端距离(<10mm)及是否切除残余胰腺癌为显著预后因素。
  • 按再次胰腺切除后复发模式:无复发组中位生存30.5个月,局部复发组32.0个月,远处转移组23.0个月。
  • 术后Clavien-Dindo III级及以上并发症发生率为8.9%,90天死亡率为1.1%。

临床怎么用

  • 对残余胰腺复发胰腺癌患者,可考虑再次手术切除以改善生存,尤其筛选年轻、健康、肿瘤较小且距胰断端至少10mm的候选者。
  • 再次胰腺切除的安全性可接受,围术期需关注Clavien-Dindo III级及以上并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A therapeutic strategy has not been established for recurrent pancreatic cancer in the remnant pancreas. The purpose of this multicenter survey was to clarify the clinical features of remnant pancreatic cancer and to assess the appropriate operative indications. METHODS: Clinical data from 114 patients with remnant pancreatic cancer after initial pancreatectomy were collected retrospectively. Clinicopathologic factors and overall survival curves were analyzed, and multivariate Cox proportional hazard models were evaluated. RESULTS: Variate analysis revealed that age (≥65 years), body mass index (<20 kg/m2), tumor size (≥20 mm), distance from the pancreatic stump (<10 mm), and resection of the remnant pancreatic cancer were significant prognostic factors. The median survival times of the resected (n = 90) and the nonresected group (n = 24) were 26 and 14 months, respectively (hazard ratio: 0.56; P = .012). When the patients were classified based on recurrence patterns after a second pancreatectomy, the median survival times were 30.5 months in the no recurrence group, 32.0 in the local recurrence group, and 23.0 in the distant metastasis group. A total of 8.9% of the patients had a postoperative complication of Clavien-Dindo classification III or higher, and the 90-day mortality rate was 1.1%. CONCLUSION: Resection of the remnant pancreatic cancer could offer a favorable outcome and a chance for a cure. In particular, a young and healthy patient with a relatively small tumor at least 10 mm away from the pancreatic stump appears to be the best candidate for reoperation. Furthermore, the safety profile of resection is acceptable.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Yamada S, Kobayashi A, Nakamori S, et al. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: Results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Surgery. 2018. PMID: 30068484. doi:10.1016/j.surg.2018.05.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。